Science has gained deep understanding of T-regulatory (Treg) cells and how to use them for therapeutical purposes in auto-immune diseases. This is what three leading research institutes in Europe showed in a peer-reviewed article in Frontiers in Immunology, the world’s fifth-most cited immunology journal. Contributors were PolTREG S.A. CEO Prof. Piotr Trzonkowski, and researchers from the groups of Prof. Ye Htun Oo at the University of Birmingham, Prof. Anke Fuchs from the Technical University of Dresden (Technische Universität Dresden), and Prof. Natalia Maria Marek- Trzonkowska from the International Centre for Cancer Vaccine Science, University of Gdansk. PolTREG is developing a comprehensive and exciting pipeline of new therapeutics, tapping into the full potential that Treg cells offer as disease-modifying treatment for conditions such as Type-1 Diabetes and Multiple Sclerosis, including next-generation engineered Treg cells.
Prof. Piotr Trzonkowski co-authors peer-reviewed article showing scientific progress in T-regautoimmune therapy
See other news
PolTREG appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to help it build partnerships across industry and deliver milestones
Global institutional investors and investment funds hold over 25% of PolTREG’s shares.
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
The J.P. Morgan Healthcare Conference 2024 is already behind us!
PolTREG at J.P. Morgan Healthcare Conference
PolTREG completes next stage of state-of-the-art manufacturing facility
“The promises of Treg autoimmune therapy – all in one hand” – PolTREG publishes new investor slide deck
First GMP-compliant Treg cellular product released from new Poltreg’s Plant!